Introduction Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV)
use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication …

Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus
vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global …

Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal
and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus …

Background Continued emergence and spread of circulating vaccine-derived type 2
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …

Abstract In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the
cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak …

Background Sabin strains used in oral poliovirus vaccines (OPV) can revert to virulence and,
in rare instances, cause disease or generate vaccine-derived strains leading to outbreaks in …

Abstract In early 2020, the COVID-19 pandemic led to substantial disruptions in global
activities. The disruptions also included intentional and unintentional reductions in health …

Despite exhaustive and fully-financed plans to manage the risks of globally coordinated
cessation of oral poliovirus vaccine (OPV) containing type 2 (OPV2) prior to 2016, as of …

Prior modeling studies showed that current outbreak management strategies are unlikely to
stop outbreaks caused by type 1 wild polioviruses (WPV1) or circulating vaccine-derived …

Background Despite multiple revisions of targets and timelines in polio eradication plans
since 1988, including changes in supplemental immunization activities (SIAs) that increase …